EditorialKommentar
Bridging the Evidence Gap: Sotrovimab Use in Pregnancy and the Need for Comprehensive Drug Safety Data
Drug Safety · 2024
DOI: 10.1007/s40264-024-01457-x ↗Kurz gefasst
Editorial in der Zeitschrift Drug Safety, 2024. Verfasst von Ursula Winterfeld. Beteiligte Einrichtung: Swiss Teratogen Information Service (STIS) and Clinical Pharmacology Service, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antibodies, Monoclonal, HumanizedHumansPregnancyFemalePregnancy ComplicationsEvidence Gaps
Substanzen
Antibodies, Monoclonal, Humanized
Autor:innen und Institutionen
- Swiss Teratogen Information Service (STIS) and Clinical Pharmacology Service, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland. ursula.winte…
Zitieren
APA
Winterfeld, U. (2024). Bridging the Evidence Gap: Sotrovimab Use in Pregnancy and the Need for Comprehensive Drug Safety Data. Drug Safety. https://doi.org/10.1007/s40264-024-01457-x
Vancouver
Winterfeld U. Bridging the Evidence Gap: Sotrovimab Use in Pregnancy and the Need for Comprehensive Drug Safety Data. Drug Safety. 2024. doi:10.1007/s40264-024-01457-x
BibTeX
@article{Winterfeld2024,
author = {Winterfeld, Ursula},
title = {Bridging the Evidence Gap: Sotrovimab Use in Pregnancy and the Need for Comprehensive Drug Safety Data},
journal = {Drug Safety},
year = {2024},
doi = {10.1007/s40264-024-01457-x}
}
EUVIMED